News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
29-Jan-2007 - Biogen Idec announced that it has initiated a Phase III randomized, double-blind study of an investigational anti-CD80 monoclonal antibody, galiximab, for patients with lymphoma. The trial will compare treatment with galiximab in combination with rituximab (RITUXAN®) to rituximab in combination ...
12-Jan-2007 - Biogen Idec announced that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS). The DEFINE (determination of the efficacy and safety of oral fumarate in relapsing-remitting MS) and CONFIRM (comparator and an ...
08-Jan-2007 - Biogen Idec and Syntonix Pharmaceuticals announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen Idec. Syntonix, a privately held biopharmaceutical company focused on discovering and developing long-acting therapeutic products to improve treatment ...
22-Sep-2006 - Biogen Idec and Alnylam Pharmaceuticals, Inc. announced a collaboration to discover and develop RNAi therapeutics for the potential treatment of progressive multifocal leukoencephalopathy (PML). PML is caused by infection of the central nervous system with a virus called "JC virus" and can occur ...
18-Sep-2006 - Biogen Idec and mondoBIOTECH AG announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH). Under terms of the agreement, ...
30-Aug-2006 - Genentech, Inc. and Biogen Idec, Inc. announced that a Phase II study of Rituxan® (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions ...
17-Aug-2006 - Researchers at Biogen Idec reported in the Journal of Immunology that activation of a recently discovered inflammation pathway may play an important role in the disease process that causes rheumatoid arthritis (RA). The studies advance the understanding of RA and demonstrate that inhibiting the ...
07-Aug-2006 - Amorfix Life Sciences Ltd. has entered into a research and investment agreement with Biogen Idec of Cambridge, Massachusetts, which includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against the ...
25-Jul-2006 - Biogen Idec and Elan Corporation, plc announced the commercial availability of TYSABRI(R) (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.S. As previously announced, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License ...
06-Jun-2006 - Biogen Idec and Fumapharm AG, a privately held pharmaceutical company, announced that they have signed a definitive agreement for the acquisition of Fumapharm by Biogen Idec. Fumapharm AG, founded in Switzerland in 1983, develops therapeutics derived from fumaric acid esters for patients with ...
© 1997-2024 LUMITOS AG, All rights reserved